Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.
Vlahovic G, Meadows KL, Hatch AJ, Jia J, Nixon AB, Uronis HE, Morse MA, Selim MA, Crawford J, Riedel RF, Zafar SY, Howard LA, O'Neill M, Meadows JJ, Haley ST, Arrowood CC, Rushing C, Pang H, Hurwitz HI. Vlahovic G, et al. Among authors: nixon ab. Oncologist. 2018 Jul;23(7):782-790. doi: 10.1634/theoncologist.2016-0377. Epub 2018 Mar 23. Oncologist. 2018. PMID: 29572245 Free PMC article. Clinical Trial.
Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors.
Strickler JH, Starodub AN, Jia J, Meadows KL, Nixon AB, Dellinger A, Morse MA, Uronis HE, Marcom PK, Zafar SY, Haley ST, Hurwitz HI. Strickler JH, et al. Among authors: nixon ab. Cancer Chemother Pharmacol. 2012 Aug;70(2):251-8. doi: 10.1007/s00280-012-1911-1. Epub 2012 Jun 29. Cancer Chemother Pharmacol. 2012. PMID: 22744359 Free PMC article. Clinical Trial.
A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.
Uronis HE, Bendell JC, Altomare I, Blobe GC, Hsu SD, Morse MA, Pang H, Zafar SY, Conkling P, Favaro J, Arrowood CC, Cushman SM, Meadows KL, Brady JC, Nixon AB, Hurwitz HI. Uronis HE, et al. Among authors: nixon ab. Oncologist. 2013;18(3):271-2. doi: 10.1634/theoncologist.2012-0404. Epub 2013 Mar 13. Oncologist. 2013. PMID: 23485624 Free PMC article. Clinical Trial.
Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment.
Hanks BA, Holtzhausen A, Evans KS, Jamieson R, Gimpel P, Campbell OM, Hector-Greene M, Sun L, Tewari A, George A, Starr M, Nixon AB, Augustine C, Beasley G, Tyler DS, Osada T, Morse MA, Ling L, Lyerly HK, Blobe GC. Hanks BA, et al. Among authors: nixon ab. J Clin Invest. 2013 Sep;123(9):3925-40. doi: 10.1172/JCI65745. Epub 2013 Aug 8. J Clin Invest. 2013. PMID: 23925295 Free PMC article.
122 results